Previous 10 | Next 10 |
Assertio Therapeutics (NASDAQ:ASRT): Q3 GAAP EPS of $0.08 beats by $0.24. Revenue of $25.47M (-26.2% Y/Y) beats by $3.43M. Press Release FY21 Guidance: GAAP net product sales is seen in the range of more than $103M vs. prior $91.0 - $96.0M while adj. EBITDA is seen greater than $43M vs. ...
Raises Full Year Net Product Sales and Non-GAAP Adjusted EBITDA Guidance Net Product Sales of $26.0 Million Quarterly Net Cash Flows from Operating Activities of $4.7 Million, Representing Second Consecutive Quarter of Positive Cash Flows from Operating Activit...
LAKE FOREST, Ill., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it will release third quarter 2021 financial results on Thursday, November 4, 2021, after the close of markets. Followin...
LAKE FOREST, Ill., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or “the Company”) (NASDAQ: ASRT) today announced that the Company’s Chief Executive Officer, Dan Peisert, and Chief Financial Officer, Paul Schwichtenberg, will presen...
Gainers: NanoVibronix (NASDAQ:NAOV) +47%. Enlivex Therapeutics (NASDAQ:ENLV) +20%. GoHealth (NASDAQ:GOCO) +16%. Travere Therapeutics (NASDAQ:TVTX) +16%. Collegium Pharmaceutical (NASDAQ:COLL) +16%. Auddia (NASDAQ:AUUD) +15%. AudioEye (NASDAQ:AEYE) +14%. Cohen & Company (NYSE:COHN) +14%. F...
The following slide deck was published by Assertio Holdings, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Assertio Holdings, Inc. 2021 Q2 - Results - Earnings Call Presentation
Assertio Holdings, Inc. (ASRT) Q2 2021 Results Earnings Conference Call August 5, 2021, 04:30 PM ET Company Participants Max Nemmers - Head-Investor Relations and Administration Dan Peisert - President and Chief Executive Officer Paul Schwichtenberg - Senior Vice President and Chief Financial...
Assertio Therapeutics (NASDAQ:ASRT): Q2 GAAP EPS of -$0.32 misses by $0.24. Revenue of $25.37M (+23.0% Y/Y) beats by $4.99M. FY21 guidance: GAAP net product sales is seen in the range of $91.0 - $96.0M vs. prior $85 - $92M while adj. EBITDA is seen between $34.0 - $37.0M vs. pr...
Reported Net Product Sales of $24.8 Million Raises Full Year Net Product Sales Guidance Range Narrows Previous Non-GAAP Adjusted EBITDA Guidance Range LAKE FOREST, Ill., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio”...
LAKE FOREST, Ill., July 20, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it will release second quarter 2021 financial results on Thursday, August 5, 2021, after the close of markets. Following...
News, Short Squeeze, Breakout and More Instantly...
Assertio Therapeutics Inc. Company Name:
ASRT Stock Symbol:
NASDAQ Market:
Assertio Therapeutics Inc. Website:
LAKE FOREST, Ill., July 24, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that it will rel...
2024-07-03 07:15:03 ET H.C. Wainwright analyst issues BUY recommendation for ASRT on July 3, 2024 06:04AM ET. ASRT was trading at $1.15 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendati...
LAKE FOREST, Ill., June 05, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that Ajay Patel, Chief...